Uvax Bio, LLC, a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy volunteers in Australia.

Uvax Bio, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia. Uvax Bio will work with their Australia-based clinical research partners Avance Clinical and the Nucleus Network study site to initiate this study in January 2024.

Dr. Jiang Zhu, Associate Professor of Integrative Structural and Computational Biology at Scripps Research, and Co-founder of Uvax Bio, LLC will be presenting a review of the development of Uvax Bio’s HIV-1 vaccine candidates including the latest results from the company’s preclinical studies confirming safety and immunogenicity in rodent models. The presentation will be during the World Vaccine Congress – West Coast in Santa Clara, California on November 30th.

The International Union of Pure and Applied Chemistry (IUPAC) has selected the glycan trimming technology used by Prof. Jiang Zhu of Scripps Research, Co-founder and Chief Scientific Officer of Uvax Bio in his innovative design of HIV-1 vaccines to improve immune recognition as one of the Top Ten Emerging Technologies in Chemistry for 2023.

Uvax Bio would like to congratulate Drew Weissman and Katalin Kariko at Penn on their Nobel prize for their mRNA research. Dr. Weissman has been a Scientific Advisory Board member at Uvax Bio since inception.